142 related articles for article (PubMed ID: 8625363)
21. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
[TBL] [Abstract][Full Text] [Related]
22. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
Flavell DJ; Noss A; Pulford KA; Ling N; Flavell SU
Cancer Res; 1997 Nov; 57(21):4824-9. PubMed ID: 9354445
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
25. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
27. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
29. The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction.
John B; Herrin BR; Raman C; Wang YN; Bobbitt KR; Brody BA; Justement LB
J Immunol; 2003 Apr; 170(7):3534-43. PubMed ID: 12646615
[TBL] [Abstract][Full Text] [Related]
30. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
31. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.
Ghetie MA; Bright H; Vitetta ES
Blood; 2001 Mar; 97(5):1392-8. PubMed ID: 11222385
[TBL] [Abstract][Full Text] [Related]
32. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
[TBL] [Abstract][Full Text] [Related]
33. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
[TBL] [Abstract][Full Text] [Related]
34. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
[TBL] [Abstract][Full Text] [Related]
35. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
Lindén O; Tennvall J; Hindorf C; Cavallin-Ståhl E; Lindner KJ; Ohlsson T; Wingårdh K; Strand SE
Acta Oncol; 2002; 41(3):297-303. PubMed ID: 12195750
[TBL] [Abstract][Full Text] [Related]
36. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules.
van Horssen PJ; van Oosterhout YV; de Witte T; Preijers FW
Scand J Immunol; 1995 Jun; 41(6):563-9. PubMed ID: 7770726
[TBL] [Abstract][Full Text] [Related]
38. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
39. Difference in CD22 molecules in human B cells and basophils.
Toba K; Hanawa H; Fuse I; Sakaue M; Watanabe K; Uesugi Y; Higuchi W; Takahashi M; Aizawa Y
Exp Hematol; 2002 Mar; 30(3):205-11. PubMed ID: 11882357
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]